The AtaiBeckley acquisition would be the largest psychedelic deal to date.
Add Axios as your preferred source to
see more of our stories on Google.
Illustration: Aïda Amer/Axios
Eli Lilly (NYSE: LLY) has agreed to buy AtaiBeckley (Nasdaq: ATAI), a psychedelic treatment developer, for up to $3.8 billion.
Why it matters: Pharmaceutical giants, previously hesitant to dabble with psychedelics, have started to sample.
Lilly to buy AtaiBeckley for $2.8B, further validating psychedelics
Lilly bets $2.8B upfront on psychedelics in deal to buy AtaiBeckley
Eli Lilly to acquire psychedelics-focused biotech AtaiBeckley
Eli Lilly to buy psychedelics maker AtaiBeckley for $2.8 billion as experimental treatments gain traction
Lilly enters psychedelic drug race with up to $3.8 billion AtaiBeckley deal
Weight-loss drugmaker Lilly nears $1.97 bn AtaiBeckley's acquisition: Report
AtaiBeckley Shares Surge as Eli Lilly Seals $3.8B Acquisition Deal - Eli Lilly (NYSE:LLY), AtaiBeckley (N
AtaiBeckley (ATAI) Stock Skyrockets 65% After-Hours on Eli Lilly Acquisition Talks - Eli Lilly (NYSE:LLY)
Eli Lilly punta sugli psichedelici: acquisirà AtaiBeckley per 2,8 miliardi di dollari | MilanoFinanza News
Eli Lilly scommette sulla salute mentale: acquisita AtaiBeckley per 2,8 miliardi di dollari
The latest in a prolific streak of buyouts by Lilly is the strongest sign yet that large pharmaceutical companies may finally be…
Eli Lilly will buy psychedelic drug developer AtaiBeckley for $2.8 billion upfront, showing big pharma’s increasing interest in…
Eli Lilly is buying the psychedelics-focused biotech AtaiBeckley for $2.8 billion upfront, a move that will expand its…
The deal for AtaiBeckley gives Lilly access to experimental drugs based on DMT and MDMA.
Eli Lilly will acquire AtaiBeckley for up to $3.8 billion. This deal aims to develop psychedelic treatments for depression and…
Eli Lilly is reportedly negotiating to acquire psychedelic drugmaker AtaiBeckley. AtaiBeckley shares experienced a significant…
